Shohei Beppu
Suita, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Transcriptome signature in the blood of neuromyelitis optica spectrum disorder under steroid tapering.
Journal: Frontiers in immunology
Published: October 10, 2024
Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis.
Journal: Clinical neurology and neurosurgery
Published: March 22, 2024
Food additive succinate exacerbates experimental autoimmune encephalomyelitis accompanied by increased IL-1β production.
Journal: Biochemical and biophysical research communications
Published: February 27, 2023
Does 'IgG4-related leptomeningitis' exist?
Journal: Rinsho shinkeigaku = Clinical neurology
Published: November 30, 2022
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with autoantibody-mediated neuroimmunology.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: September 28, 2022
A case of IgG4-related disease exclusively affecting pia matter and cerebral parenchyma
Journal: Rinsho shinkeigaku = Clinical neurology
Published: June 01, 2022
A case of sporadic amyotrophic lateral sclerosis (ALS) with Senataxin (SETX) gene variant
Journal: Rinsho shinkeigaku = Clinical neurology
Published: March 01, 2022
Cell-Free DNA Derived From Neutrophils Triggers Type 1 Interferon Signature in Neuromyelitis Optica Spectrum Disorder.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: October 27, 2021
High cell surface expression and peptide binding affinity of HLA-DQA1*05:03, a susceptible allele of neuromyelitis optica spectrum disorders (NMOSD).
Journal: Scientific reports
Published: September 27, 2021
Anti-AQP4 autoantibodies promote ATP release from astrocytes and induce mechanical pain in rats.
Journal: Journal of neuroinflammation
Published: February 19, 2021
Sema4A is implicated in the acceleration of Th17 cell-mediated neuroinflammation in the effector phase.
Journal: Journal of neuroinflammation
Published: November 10, 2019
Showing 1-12 of 12
Last Updated: 09/26/2026